Drug intelligence / Profile preview

CPT-060

Development stage: Preclinical
Lead developer: Enabled Therapeutics
Modality: Small Molecules

Overview

CPT-060 is an investigational drug initially developed by Enabled Therapeutics, Inc. It functions as a phosphatidylinositol 3-kinase beta (PI3Kβ) inhibitor. This small molecule is currently in preclinical development and is being explored for its therapeutic potential in neoplasms and nervous system diseases, with a specific active indication for glioblastoma.

Targets

PIK3CB (Phosphatidylinositol 3-kinase beta subunit)

Beyond the preview

Go deeper on CPT-060.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPT-060.

Explore the full profile